{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:37:24Z","timestamp":1770478644422,"version":"3.49.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This phase II trial evaluated the safety and efficacy of combining yttrium-90 (<jats:sup>90<\/jats:sup>Y) ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM) and autologous stem-cell transplantation in patients with non-Hodgkin's lymphoma who were considered ineligible for total-body irradiation because of older age or prior radiotherapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Between May 2002 and January 2006, 14 days before autologous stem-cell transplantation, 41 patients with non-Hodgkin's lymphoma received standard-dose <jats:sup>90<\/jats:sup>Y ibritumomab tiuxetan (14.8 MBq\/kg [0.4 mCi\/kg]) followed by high-dose BEAM. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The median age was 60 years (range, 19 to 78 years), and the median number of previous therapies was two (range, one to six). Disease histologies were diffuse large B-cell (n = 20), mantle cell (n = 13), follicular (n = 4), and transformed lymphoma (n = 4). With a median follow-up of 18.4 months (range, 5.5 to 53.3 months) the estimated 2-year overall and progression-free survival were 88.9% (95% CI, 75.3% to 95.2%) and 69.8% (95% CI, 56.4% to 79.7%). The median time to WBC engraftment was 11 days (range, 9 to 26 days) and time to platelet engraftment was 12 days (range, 3 to 107 days). Adverse events were similar to those seen historically with high-dose BEAM alone, and included grade 3 or 4 pulmonary toxicity in 10 patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Adding <jats:sup>90<\/jats:sup>Y ibritumomab tiuxetan to high-dose BEAM with autologous stem-cell transplantation is feasible and has a toxicity and tolerability profile similar to that observed with BEAM alone. Rates of progression-free survival seen in these patients are promising and warrant additional study. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.11.9248","type":"journal-article","created":{"date-parts":[[2007,11,20]],"date-time":"2007-11-20T02:15:08Z","timestamp":1195524908000},"page":"90-95","source":"Crossref","is-referenced-by-count":125,"title":["Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"26","author":[{"given":"Amrita","family":"Krishnan","sequence":"first","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auayporn","family":"Nademanee","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry C.","family":"Fung","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Raubitschek","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo T.","family":"Spielberger","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Falk","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joycelynne M.","family":"Palmer","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte; Oncology Research and Development, Biogen Idec, San Diego, CA; and Section of Hematology and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.104249"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2399"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2000.n.004"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.406"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi248"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.10.006"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"R18","unstructured":"Lefr\u00e8re F, Delmer A, Levy V, et al: Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica 89:1275,2004-1276,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh069"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2552"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.10.3844"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2934"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.117"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1310"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.185"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.575"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000083028"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0054"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0622"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Krishnan AY, Nademanee A, Raubitschek A, et al: A comparison of BEAM and yttrium 90 ibritumomab tiuxetan (Zevalin) in addition to BEAM (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: Impact of radioimmunotherapy on transplant outcomes. Blood 108:865a,2006,  (abstr 3043)","DOI":"10.1182\/blood.V108.11.3043.3043"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.11.9248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:13:28Z","timestamp":1653509608000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.11.9248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"alternative-id":["10.1200\/JCO.2007.11.9248"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.11.9248","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}